Pyrrolobenzodiazepines

a technology of pyrrolobenzodiazepines and di-carbinolamines, which is applied in the field of pyrrolobenzodiazepines, can solve the problems of inability to accurately assess the amount of active substances in a given amount, the balance between them may change over time, and the conversion to di-carbinolamine forms, etc., and achieve the effect of accurately assessing the amount of active substances

Inactive Publication Date: 2008-02-14
UNITED STATES OF AMERICA
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The bis-bisulphites provide a stable form of these compounds, maintaining their antitumor activity and enabling effective treatment of proliferative diseases and other gene-based conditions without the cardiotoxicity associated with previous pyrrolobenzodiazepines.

Problems solved by technology

One difficulty that this compound presents in formulation is that in water it converts to the di-carbinolamine form:
Furthermore, if the compound is isolated as a solid with a mixture of these three forms, the balance between them may change over time.
Although this does not pose a problem for administration of the compound, it can provide difficulties in accurately assessing the amount of active substance in a given amount of powder.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrrolobenzodiazepines
  • Pyrrolobenzodiazepines
  • Pyrrolobenzodiazepines

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of 1,1′[[(Propane-1,3-diyl)dioxy]bis(11aS)-11-sulpho-7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4-benzodiazepin-5-one]]sodium salt (SJG-720)

[0058]

[0059] A solution of sodium bisulphite (13.2 mg, 0.127 mmol) in water (5.2 mL) was added to a stirred solution of SJG-136 (35.19 mg, 63.3 μmol) in dichloromethane (2.5 mL, Aldrich sure seal grade). The reaction mixture was allowed to stir vigorously for 24 hours, after which time the organic and aqueous layers were separated. TLC analysis (eluent—95:5 v / v CHCl3 / MeOH) of the aqueous phase revealed absence of SJG-136 (Rf˜0.3) and presence of baseline material with strong uv absorption. The aqueous layer was lyophilised to provide the bisulphite adduct SJG-720 as a lightweight white solid (40.88 mg, 85%). Mpt. 213-216° C. [α]29D+126.2° (c=0.0317 MeOH)

example 2

Synthesis of 1,1′[[(Pentane-1,3-diyl)dioxy]bis(11aS)-11-sulpho-7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4-benzodiazepin-5-one]]sodium salt (SJG-738)

[0060]

[0061] A solution of sodium bisulphite (16.46 mg, 0.158 mmol) in water (3.0 mL) was added to a stirred solution of DRG-16 (46.2 mg, 79.1 μmol) in dichloromethane (1.5 mL, Aldrich sure seal grade). The reaction mixture was allowed to stir vigorously for 22 hours, after which time the organic and aqueous layers were separated. TLC analysis (eluent—95:5 v / v CHCl3 / MeOH) of the aqueous phase revealed absence of DRG-16 (Rf˜0.3) and presence of baseline material with strong uv absorption. The aqueous layer was lyophilised to provide the bisulphite adduct SJG-738 as a lightweight white solid (47.95 mg, 77%). Mpt. 203-204° C. [α]27D+117.6° (c=0.0425 MeOH).

[0062] Further Studies

[0063] All NMR experiments were performed using a Bruker Avance 400 MHz NMR spectrophotometer. NMR solvents were purchased from Goss S...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A compound of formula I: or solvate thereof, wherein n is 1 to 10, and M and M′ are independently selected from monovalent pharmaceutically acceptable cations, or together represent a divalent pharmaceutically acceptable cation.

Description

[0001] This application is a continuation of U.S. patent application Ser. No. 11 / 129,207, filed May 13, 2005, which is a continuation of International Application No. PCT / GB2004 / 004497, filed Oct. 22, 2004, which claims the benefit of U.S. provisional patent application No. 60 / 513,751, filed Oct. 22, 2003, the disclosures of which are incorporated by reference. [0002] The present invention relates to bisulphite derivatives of SJG-136 and DRG-16, and analogues thereof.BACKGROUND TO THE INVENTION [0003] Some pyrrolobenzodiazepines (PBDs) have the ability to recognise and bond to specific sequences of DNA; the preferred sequence is PuGPu. The first PBD antitumour antibiotic, anthramycin, was discovered in 1965 (Leimgruber, et al., J. Am. Chem. Soc., 87, 5793-5795 (1965); Leimgruber, et al., J. Am. Chem. Soc., 87, -5791-5793 (1965)). Since then, a number of naturally occurring PBDs have been reported, and over 10 synthetic routes have been developed to a variety of analogues (Thurston, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K31/5517A61P43/00C07D487/04C07D519/00
CPCC07D487/04A61P31/00A61P43/00
InventorLIU, PAUL S.VISHNUVAJJALA, B. RAOSNADER, KENNETH M.THURSTON, DAVID E.HOWARD, PHILIPGREGSON, STEPHEN
OwnerUNITED STATES OF AMERICA